Solvocef Capsule Overview
- Solvocef Capsule 500mg is an antibiotic belongs to 3rd group of fluoroquinolones. Fluoroquinolones are potent bactericidal agents against E. coli and various species of Salmonella, Shigella, Enterobacter, Campylobacter and Neisseeria, it has excellent activity against S. pneumoniae. Solvocef Capsule 500mg is used in respiratory tract infections, in urinary tract infectionsand in bone and soft tissue infections.
- Solvocef Capsule 500mg is primarily indicated in conditions like Acute bacterial sinusitis, Chronic bronchitis, Lower respiratory tract infections, Oedema, Pneumonia, Short-term treatment of severe congestive heart failure, Sinusitis, Skin infections, Soft tissue infections, Upper respiratory tract infections, and can also be given in adjunctive therapy as an alternative drug of choice in Bacterial conjunctivitis.
- The severe or irreversible adverse effects of Solvocef Capsule 500mg, which give rise to further complications include Hypotension, Hypotension, Hyperglycemia, Dyspnea, Hyperuricemia, Hyperglycemia, Hyperlipidemia. Solvocef Capsule 500mg produces potentially life-threatening effects which include Anaphylactic reactions, Atrial fibrillation, which are responsible for the discontinuation of Solvocef Capsule 500mg therapy. The symptomatic adverse reactions produced by Solvocef Capsule 500mg are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Drowsiness, Nausea, vomiting, Diarrhea, Myalgia, Restlessness, Tachycardia, Tremors, Insomnia, Abdominal pain, Sweating, Skin rash, Dyspepsia, Pseudomembranous colitis, Hemolytic anemia, Thrombocytopenia, Edema, Hot flushes, Syncope, Gynecomastia, Abnormal LFT, Hypersensitivity reactions, Taste perversion, Superinfection, QT prolongation, Visual disturbances, dizziness, dyspepsia, Abnormal LFT, agranulocytosis, arthropathy, Tachycardia.
- It should be used with caution in patients with known or suspected central nervousstem disorders which may predispose to seizures or lower the seizure threshold As no pharmacokinetics or pharmacodynamic data are available in severe hepatic impairment, the use of Solvocef Capsule 500mg in this patients group is not recommended. Solvocef Capsule 500mg should be used with caution in patients with known QT interval prolongation or uncorrected hypokalemia; in those receiving class IA (e.g quinidine or procaine amide) or class III antiarrhythmic agents (sotalol, ibutilide, amiodarone); and in patients who are receiving other agents known to increase the QT interval (e.g erythromycin, tricyclic antidepressants).